EUVIMEDEUVIMED entdecken
VergleichsstudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Chemotherapy‐Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline‐Free Regimen With Docetaxel, Cyclophosphamide—Results From a Randomized Clinical Trial

Manuel Hörner iD, Henning Schäffler, Lothar Häberle iD, Chloë Goossens iD, Kerstin Pfister, Elena Leinert, Kristina Veselinovic, Sara Y Brucker, Uwe Köhler, Georg Heinrich, Andreas Schneeweiss, Matthias W Beckmann und 5 weitere

International Journal of Cancer · 15.10.2026 · 159 (8) · 1990-2003

DOI: 10.1002/ijc.70528 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Cancer, online erschienen am 29.04.2026. Verfasst von Manuel Hörner und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Friedrich-Alexander-Uni…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Nausea, Vomiting. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi-Aventis Deutschland, Chugai Pharmaceutical, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemotherapy‐induced nausea and vomiting (CINV) remains an important side effect despite new antiemetic drugs. This study tried to understand the occurrence of CINV in patients receiving two different chemotherapy regimens. As part of the randomized controlled clinical trial SUCCESS C (NCT00847444), 1582 of the 3463 patients completed CINV diaries. Patients were randomized to receive either chemotherapy with FEC (5‐fluorouracil, epirubicin, cyclophosphamide followed by docetaxel) or TC (docetaxel, cyclophosphamide). CINV was evaluated hourly using a specially designed questionnaire. Endpoints of the study were complete response (no emesis) and total control (no nausea and no emesis) and were assessed with Kaplan–Meier curves and Cox regression analyses over three chemotherapy cycles. Eight hundred fourteen patients received FEC and 768 received TC; patients and tumor characteristics were similar in both groups. Patients receiving FEC had significantly more nausea and vomiting, with the main difference in the first 12 h. In the first cycle, the 0–12‐h nausea/emesis‐free rates were 70%/41% for FEC and 91/76% for TC. By 24 h after chemotherapy, the rates were 65%/33% (FEC) and 85%/60% (TC). The differences were similar in cycles 2 and 3. The detailed analysis of CINV in the study is unique and paves the way for modern CINV analysis of new therapeutics such as antibody‐drug conjugates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsNauseaVomitingAdultAgedFemaleHumansMiddle AgedChemotherapy, AdjuvantCyclophosphamideDocetaxelEpirubicinFluorouracilTaxoids

Stichwörter der Autor:innen

chemotherapychemotherapy‐induced nausea and vomiting (CINV)early breast cancerrandomized clinical trial

Substanzen

CyclophosphamideDocetaxelEpirubicinFluorouracilTaxoids

Autor:innen und Institutionen

  • Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
  • Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany.
  • Biostatistics Unit, Department of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Erlangen, Germany.
  • Department of Women's Health, Tuebingen University, Tuebingen, Germany.
  • Department of Gynecology and Obstetrics, Klinikum St. Georg, Leipzig, Germany.
  • Schwerpunktpraxis der Gynäkologie und Onkologie Fürstenwalde, Klinikum Offenbach, Fürstenwalde, Germany.

ORCID-Profile: Manuel Hörner, Lothar Häberle, Chloë Goossens, Peter A Fasching

Förderung

  • Sanofi-Aventis Deutschland
  • Chugai Pharmaceutical
  • Pfizer
  • GlaxoSmithKline

Zitieren

APA

Hörner, M., Schäffler, H., Häberle, L., Goossens, C., Pfister, K., Leinert, E., Veselinovic, K., Brucker, S. Y., Köhler, U., Heinrich, G., Schneeweiss, A., Beckmann, M. W., Fasching, P. A., Janni, W., Rack, B., Heublein, S., & Ziegler, P. (2026). Chemotherapy‐Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline‐Free Regimen With Docetaxel, Cyclophosphamide—Results From a Randomized Clinical Trial. International Journal of Cancer, 159(8), 1990-2003. https://doi.org/10.1002/ijc.70528

Vancouver

Hörner M, Schäffler H, Häberle L, Goossens C, Pfister K, Leinert E, et al. Chemotherapy‐Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline‐Free Regimen With Docetaxel, Cyclophosphamide—Results From a Randomized Clinical Trial. International Journal of Cancer. 2026;159(8):1990-2003. doi:10.1002/ijc.70528

BibTeX
@article{Hrner2026,
  author = {Hörner, Manuel and Schäffler, Henning and Häberle, Lothar and Goossens, Chloë and Pfister, Kerstin and Leinert, Elena and Veselinovic, Kristina and Brucker, Sara Y and Köhler, Uwe and Heinrich, Georg and Schneeweiss, Andreas and Beckmann, Matthias W and Fasching, Peter A and Janni, Wolfgang and Rack, Brigitte and Heublein, Sabine and Ziegler, Philipp},
  title = {Chemotherapy‐Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline‐Free Regimen With Docetaxel, Cyclophosphamide—Results From a Randomized Clinical Trial},
  journal = {International Journal of Cancer},
  year = {2026},
  volume = {159},
  number = {8},
  pages = {1990--2003},
  doi = {10.1002/ijc.70528}
}
Kostenlos starten →